Article Text

Download PDFPDF
Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy

Statistics from


  • Source of funding National Board of Health in Denmark and the Wørzner foundation.


  • Competing interests AK is principal investigator of over 330 clinical trials sponsored by over 55 pharmaceutical companies and 30 clinical research organisations.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles